For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Docetaxel market for 2018-2023.
Docetaxel is a chemotherapy medication used to treat a number of types of Cancer. This includes breast Cancer, head and neck Cancer, stomach Cancer, Prostate Cancer and non-small-cell lung Cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein.
The classification of Docetaxel includes 20 mg/ml, 40 mg/ml and 60 mg/ml. And the proportion of 20 mg/ml in 2017 is about 86% and the proportion is stable from 2013 to 2017.
Docetaxel is widely used For Breast Cancer, Prostate Cancer, Non-small Cell Lung Cancer and Cancer. The most proportion of Docetaxel used for Breast Cancer and the proportion in 2017 is 85%.
Over the next five years, LPI(LP Information) projects that Docetaxel will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Docetaxel market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
- 20 mg/ml
- 40 mg/ml
- 60 mg/ml
Segmentation by application:
- Breast Cancer
- Prostate Cancer
- Non-small Cell Lung Cancer
- Other
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- - Spain
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
- Hengrui Medicine
- Sanofi
- Qilu Pharma
- Shenzhen Main Luck Pharma
- Jiangsu Aosaikang Pharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
- To study and analyze the global Docetaxel consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
- To understand the structure of Docetaxel market by identifying its various subsegments.
- Focuses on the key global Docetaxel manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
- To analyze the Docetaxel with respect to individual growth trends, future prospects, and their contribution to the total market.
- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
- To project the consumption of Docetaxel submarkets, with respect to key regions (along with their respective key countries).
- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
- To strategically profile the key players and comprehensively analyze their growth strategies.